Healthy Volunteers
Conditions
Keywords
First in human, subjects
Brief summary
This study is designed to evaluate the safety and tolerability of UCB7858 when given as single ascending doses administered by intravenous or subcutaneous infusion in healthy subjects.
Interventions
DRUGUCB7858
DRUGPlacebo
Sponsors
UCB Biopharma S.P.R.L.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male and female volunteers who gave their written consent by signing the Informed Consent Form * Subjects in the age between 18 and 55 years old with normal weight as determined by a body mass index (BMI) between 18 and 30 kg/m\^2, with a body weight of at least 50 kg for male subjects or 45 kg for female subjects * Subject has clinical laboratory test results within the reference ranges of the testing laboratory or outside the reference range of the laboratory but considered as not clinically significant by the Investigator * Subjects has blood pressure (BP) and pulse within normal range in a supine position after 5 minutes rest * Subject's electrocardiogram (ECG) is considered normal or abnormal but clinically non significant * Female subjects of childbearing potential must agree to use a highly effective method of birth control during the study and for a period of 6 months after dosing of IMP
Exclusion criteria
* Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study: Subject has any acute or chronic illness which, in the opinion of the Investigator, may place the subject at risk because of participation in the study. Subject has any clinically relevant abnormal findings in physical examination, laboratory tests, vital signs, or ECG, which, in the opinion of the Investigator, may place the subject at risk because of participation in the study. * Tests positive for Human Immunodeficiency Virus (HIV)-1 or-2 antibodies, Hepatitis B Virus (HBV) surface antigen, or Hepatitis C Virus (HCV) antibody at Screening * Any of the following hematological function tests at the Screening Visit: Hemoglobin \<111g/L (for women) or \<113g/L (for men) * Absolute neutrophil count \<1.5x10\^9/L (\<1000/mm\^3); Platelets \<150x10\^9/L * Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study or within 6 months following the final dose of the IMP For subjects enrolled in the cohorts where the skin biopsies will be performed (Cohort 7 onward), the following
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events following administration of UCB7858 | Cohort 1-10: Day 1 up to Day 72 Cohort 11: Day 1 up to Day 120 |
Secondary
| Measure | Time frame |
|---|---|
| Time to reach Cmax (tmax) | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Area under the curve from time 0 to time t, the time of last quantifiable concentration [AUC(0-t)] | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Area under the curve from 0 to infinity (AUC) | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| The terminal plasma half-life (t1/2) following intravenous administration | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Plasma clearance (CL) of UCB7858 following intravenous administration | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Maximum plasma concentration (Cmax) | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Apparent volume of distribution (Vss/F) of UCB7858 following subcutaneous administration | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Apparent plasma clearance (CL/F) of UCB7858 following subcutaneous administration | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Mean absolute bioavailability (F) of UCB7858 given subcutaneously, using the ratio of geometric mean AUCs for subcutaneous (sc) administration and intravenous (iv) infusion (AUC_sc/AUC_iv) | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Concentration of UCB7858 at the end of infusion (Cinf) | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Time at the end of infusion of UCB7858 (tinf) | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
| Volume of distribution (Vss) for UCB7858 at steady state following intravenous administration | Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 |
Countries
United Kingdom
Outcome results
None listed